|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
11
|
|
pubmed:dateCreated |
1996-12-17
|
|
pubmed:abstractText |
To determine the maximum-tolerable dose (MTD) of fluorouracil (5FU) when given with fixed doses of leucovorin and irinotecan (CPT-11), to define the dose-limiting toxicities of this combination, and to evaluate the effect of 5FU on the pharmacokinetics of CPT-11.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
0732-183X
|
|
pubmed:author |
pubmed-author:BerkeryRR,
pubmed-author:DietzAA,
pubmed-author:EngMM,
pubmed-author:KanowitzJJ,
pubmed-author:KelsenD PDP,
pubmed-author:KemenyN ENE,
pubmed-author:LockerPP,
pubmed-author:SaltzL BLB,
pubmed-author:SchaafLL,
pubmed-author:SpriggeJJ,
pubmed-author:StatonB ABA,
pubmed-author:StegerCC
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
14
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2959-67
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:8918493-Adult,
pubmed-meshheading:8918493-Aged,
pubmed-meshheading:8918493-Antidotes,
pubmed-meshheading:8918493-Antineoplastic Agents, Phytogenic,
pubmed-meshheading:8918493-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:8918493-Camptothecin,
pubmed-meshheading:8918493-Diarrhea,
pubmed-meshheading:8918493-Female,
pubmed-meshheading:8918493-Fluorouracil,
pubmed-meshheading:8918493-Humans,
pubmed-meshheading:8918493-Leucovorin,
pubmed-meshheading:8918493-Male,
pubmed-meshheading:8918493-Middle Aged,
pubmed-meshheading:8918493-Neoplasms
|
|
pubmed:year |
1996
|
|
pubmed:articleTitle |
Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, and leucovorin in patients with advanced solid tumors.
|
|
pubmed:affiliation |
Gastrointestinal Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA. SALTZL@MSKCC.ORG
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase I
|
